Oral GLP-1s getting closer

Healthed

writer

Healthed

Healthed

Lilly releases topline trial results for its daily pill; Novo Nordisk awaits FDA decision on its own oral formulation…

Lilly released topline trial results for its oral GLP-1, orforglipron, on Thursday night, announcing an average weight loss of 12.4% and 12.4 kg among participants taking the highest dose (36mg).

The phase 3 ATTAIN-1 trial compared the daily pill against placebo at 72 weeks.

“In a key secondary endpoint, 59.6% of participants taking the highest dose of orforglipron lost at least 10% of their body weight, while 39.6% lost at least 15% of their body weight,” according to Lilly’s press release.

Patients taking the 12mg dose lost an average of 9.3% of their body weight, while those taking the 6mg dose lost an average of 7.8%.

By contrast, in the SURMOUNT-1 trial, Lilly’s injectable weight loss drug tirzepatide achieved average weight loss of approximately 15% at the 5mg dose, 19.5% at the 10 mg dose and 20.9% at the 15mg dose.

In May, Novo Nordisk filed an application to the FDA for its oral formulation of semaglutide in a 25mg dose, with participants reportedly achieving an average reduction of 13.6% of their body weight. A decision from the FDA is expected in Q4 this year.

Lilly says the detailed ATTAIN-1 results will be presented in September at the European Association for the Study of Diabetes Annual Meeting 2025 and published in a peer-reviewed journal.

Watch this space.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Dr Kate Walsh

Dr Kate Walsh

Endometriosis Cases – Practical Guide

Prof Finlay Macrae AO

Prof Finlay Macrae AO

Familial Colorectal Cancer

Prof Richard Harvey

Prof Richard Harvey

Recurrent Nasal Polyps Management – When to Refer

Prof Terence O'Brien

Prof Terence O'Brien

SUDEP – What is it and How to Reduce the Risk

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.

Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.

We invite you to join the upcoming Healthed webcast where Prof Macrae speak on how GPs can suspect, assess and manage hereditary colorectal cancer risk.

Tuesday 2nd September, 7pm AEST